Home / Publications / Novel 2-amino-substituted (thio)morpholine-3,5-diones: synthesis and cytotoxicity studies

Novel 2-amino-substituted (thio)morpholine-3,5-diones: synthesis and cytotoxicity studies

Markas G Kasparavichius 1
Markas G Kasparavichius
, 
Danil Ivanovich Weber 1
Danil Ivanovich Weber
, 
Alexander Siyasatovich Bunev 1, 2
Alexander Siyasatovich Bunev
, 
Alexander Vladimirovich Sapegin 1
Alexander Vladimirovich Sapegin
1 Institute of Chemistry, St. Petersburg State University, St. Petersburg, Russian Federation
2 Medicinal Chemistry Centre, Togliatti State University, Togliatti, Russian Federation
10.1016/j.mencom.2024.02.032
Published 2024-02-19
Communication , Volume 34, Issue 2, 262-264
1
Share
Cite this
GOST
 | 
Cite this
GOST Copy
Kasparavichius M. G. et al. Novel 2-amino-substituted (thio)morpholine-3,5-diones: synthesis and cytotoxicity studies // Mendeleev Communications. 2024. Vol. 34. No. 2. pp. 262-264.
GOST all authors (up to 50) Copy
Kasparavichius M. G., Weber D. I., Bunev A. S., Sapegin A. V. Novel 2-amino-substituted (thio)morpholine-3,5-diones: synthesis and cytotoxicity studies // Mendeleev Communications. 2024. Vol. 34. No. 2. pp. 262-264.
RIS
 | 
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/j.mencom.2024.02.032
UR - https://mendcomm.colab.ws/publications/10.1016/j.mencom.2024.02.032
TI - Novel 2-amino-substituted (thio)morpholine-3,5-diones: synthesis and cytotoxicity studies
T2 - Mendeleev Communications
AU - Kasparavichius, Markas G
AU - Weber, Danil Ivanovich
AU - Bunev, Alexander Siyasatovich
AU - Sapegin, Alexander Vladimirovich
PY - 2024
DA - 2024/02/19
PB - Mendeleev Communications
SP - 262-264
IS - 2
VL - 34
ER -
BibTex
 | 
Cite this
BibTex (up to 50 authors) Copy
@article{2024_Kasparavichius,
author = {Markas G Kasparavichius and Danil Ivanovich Weber and Alexander Siyasatovich Bunev and Alexander Vladimirovich Sapegin},
title = {Novel 2-amino-substituted (thio)morpholine-3,5-diones: synthesis and cytotoxicity studies},
journal = {Mendeleev Communications},
year = {2024},
volume = {34},
publisher = {Mendeleev Communications},
month = {Feb},
url = {https://mendcomm.colab.ws/publications/10.1016/j.mencom.2024.02.032},
number = {2},
pages = {262--264},
doi = {10.1016/j.mencom.2024.02.032}
}
MLA
Cite this
MLA Copy
Kasparavichius, Markas G., et al. “Novel 2-amino-substituted (thio)morpholine-3,5-diones: synthesis and cytotoxicity studies.” Mendeleev Communications, vol. 34, no. 2, Feb. 2024, pp. 262-264. https://mendcomm.colab.ws/publications/10.1016/j.mencom.2024.02.032.

Keywords

5-dione
amines
Cereblon.
cytotoxicity studies
Halogenation
immunomodulatory drugs
morpholine-3
nucleophilic substitution reaction
thiomorpholine-3

Abstract

The present study explores the synthesis of new potential Cereblon ligands, 2-amino derivatives of (thio)morpholine-3,5-diones. The resulting compounds demonstrate notable cytotoxic effects in tests conducted in vitro on myeloma cell lines, highlighting the potential of these compounds as molecular glues.

References

.
Bivalent Ligands for Protein Degradation in Drug Discovery
Scheepstra M., Hekking K.F., van Hijfte L., Folmer R.H.
Computational and Structural Biotechnology Journal, 2019
.
PROTAC targeted protein degraders: the past is prologue
Békés M., Langley D.R., Crews C.M.
Nature Reviews Drug Discovery, 2022
.
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke J., Udeshi N.D., Narla A., Grauman P., Hurst S.N., McConkey M., Svinkina T., Heckl D., Comer E., Li X., Ciarlo C., Hartman E., Munshi N., Schenone M., Schreiber S.L., et. al.
Science, 2014
.
Easy Access to New Heterocyclic Systems:  1,4-Oxazine and Substituted 1,4-Oxazines
Claveau E., Gillaizeau I., Blu J., Bruel A., Coudert G.
Journal of Organic Chemistry, 2007
.
The Preparation of 1,4-Thiazine
Barkenbus C., Landis P.S.
Journal of the American Chemical Society, 1948
.
Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma
Zhu Y.X., Braggio E., Shi C., Kortuem K.M., Bruins L.A., Schmidt J.E., Chang X., Langlais P., Luo M., Jedlowski P., LaPlant B., Laumann K., Fonseca R., Bergsagel P.L., Mikhael J., et. al.
Blood, 2014
.
The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Lu G., Middleton R.E., Sun H., Naniong M., Ott C.J., Mitsiades C.S., Wong K., Bradner J.E., Kaelin W.G.
Science, 2014
.
Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy
Thakurta A., Gandhi A.K., Waldman M.F., Bjorklund C., Ning Y., Mendy D., Schafer P., Lopez-Girona A., Lentzsch S., Schey S.A., Calle Y., Chelliah R., Orlowski R.Z., Madan A., Avet-Loiseau H., et. al.
Leukemia, 2013
.
The evolution of thalidomide and its IMiD derivatives as anticancer agents
Bartlett J.B., Dredge K., Dalgleish A.G.
Nature Reviews Cancer, 2004